scholarly journals Cyclooxygenase-2 Inhibition Does Not Improve the Reduction in Ductal Carcinoma In situ Proliferation with Aromatase Inhibitor Therapy: Results of the ERISAC Randomized Placebo-Controlled Trial

2010 ◽  
Vol 16 (5) ◽  
pp. 1605-1612 ◽  
Author(s):  
Nigel J. Bundred ◽  
Angela Cramer ◽  
Julie Morris ◽  
Lorna Renshaw ◽  
Kwok-Leung Cheung ◽  
...  
Cancer ◽  
2016 ◽  
Vol 123 (6) ◽  
pp. 940-947 ◽  
Author(s):  
Hui Zhao ◽  
Nainan Hei ◽  
Yiling Wu ◽  
Winston Chan ◽  
Xiudong Lei ◽  
...  

Author(s):  
Stephen Kinsey-Trotman ◽  
Zumin Shi ◽  
Beverley Fosh

This review paper analyzed publications of adjuvant tamoxifen and aromatase inhibitor use following surgery for breast ductal carcinoma in situ (DCIS). Key endpoint analyses were risk of invasive and noninvasive malignancies and new contralateral breast cancers. Meta-analysis of three studies showed a relative risk of 0.69 (95% confidence interval, 0.60-0.79, P<0.05) for breast malignancies with tamoxifen treatment in a mixed radiotherapy treatment/naïve cohort. Subgroup analysis of DCIS populations in multiple studies showed a trend to benefit with aromatase inhibitor treatment.


Sign in / Sign up

Export Citation Format

Share Document